Expression of HuR in Merkel cell carcinoma and in normal skin

Journal of Cutaneous Pathology

Volumn 35, Issue 1, 2008, Pages 10-14

  Koljonen, Virve ^a,c   Böhling, Tom ^a   Haglund, Caj ^a   Ristimäki, Ari ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Toolo Hospital   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

HUR PROTEIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EPIDERMIS; FEMALE; HAIR FOLLICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MALE; MERKEL CELL TUMOR; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SEBACEOUS GLAND; SKIN CARCINOGENESIS;

AGED; ANTIGENS, SURFACE; CARCINOMA, MERKEL CELL; CELL NUCLEUS; CYTOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; MALE; NEOPLASM PROTEINS; RNA-BINDING PROTEINS; SKIN; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 37249054582     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2007.00762.x     Document Type: Article

References (26)

1. Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol 2003 49: 832.
2. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005 89: 1.
3. Koljonen V, Bohling T, Granhroth G, Tukiainen E. Merkel cell carcinoma: a clinicopathological study of 34 patients. Eur J Surg Oncol 2003 29: 607.
4. Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci 1995 20: 465.
5. Brennan CM, Steitz JA. HuR and mRNA stability. Cell Mol Life Sci 2001 58: 266.
6. Chung S, Jiang L, Cheng S, Furneaux H. Purification and properties of HuD, a neuronal RNA-binding protein. J Biol Chem 1996 271: 11518.
7. Ma C, Wang J, Luo J. Exposure to asphalt fumes activates activator protein-1 through the phosphatidylinositol 3-kinase/Akt signaling pathway in mouse epidermal cells. J Biol Chem 2003 278: 44265.
8. Levine TD, Gao F, King PH, Andrews LG, Keene JD. Hel-N1: an autoimmune RNA-binding protein with specificity for 3′ uridylate-rich untranslated regions of growth factor mRNAs. Mol Cell Biol 1993 13: 3494.
9. Good PJ. A conserved family of elav-like genes in vertebrates. Proc Natl Acad Sci U S A 1995 92: 4557.
10. Szabo A, Dalmau J, Manley G, et al. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elav and Sex-lethal. Cell 1991 67: 325.
11. Dalmau J, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer - a quantitative western blot analysis. Ann Neurol 1990 27: 544.
12. Greenlee JE, Steffens JD, Clawson SA, Hill K, Dalmau J. Anti-Hu antibodies in Merkel cell carcinoma. Ann Neurol 2002 52: 111.
13. Gallouzi IE, Steitz JA. Delineation of mRNA export pathways by the use of cell-permeable peptides. Science 2001 294: 1895.
14. Lopez de Silanes I, Fan J, Yang X, et al. Role of the RNA-binding protein HuR in colon carcinogenesis. Oncogene 2003 22: 7146.
15. Heinonen M, Bono P, Narko K, et al. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 2005 65: 2157.
16. Erkinheimo TL, Lassus H, Sivula A, et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res 2003 63: 7591.
17. Denkert C, Weichert W, Pest S, et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 2004 64: 189.
18. Mrena J, Wiksten JP, Thiel A, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res 2005 11: 7362.
19. Koljonen V, Böhling T, Tukiainen E, Haglund C, Jahkola T. Tenascin-C expression in Merkel cell carcinoma lymphnode metastasis. APMIS 2006 114: 39.
20. Denkert C, Weichert W, Winzer KJ, et al. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin Cancer Res 2004 10: 5580.
21. Denkert C, Koch I, von Keyserlingk N, et al. Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Mod Pathol 2006 19: 1261.
22. Atasoy U, Watson J, Patel D, Keene JD. ELAV protein HuA (HuR) can redistribute between nucleus and cytoplasm and is upregulated during serum stimulation and T cell activation. J Cell Sci 1998 111: 3145.
23. Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ. Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 2003 278: 37637.
24. Yang X, Wang W, Fan J, et al. Prostaglandin A2-mediated stabilization of p21 mRNA through an ERK-dependent pathway requiring the RNA-binding protein HuR. J Biol Chem 2004 279: 49298.
25. Fernandez-Figueras MT, Puig L, Musulen E, et al. Expression profiles associated with aggressive behavior in Merkel cell carcinoma. Mod Pathol 2007 20: 90.
26. Houben R, Michel B, Vetter-Kauczok CS, et al. Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma. J Invest Dermatol 2006 126: 1135.